<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456794</url>
  </required_header>
  <id_info>
    <org_study_id>6002-US-006</org_study_id>
    <nct_id>NCT00456794</nct_id>
  </id_info>
  <brief_title>12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa</brief_title>
  <official_title>A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and&#xD;
      efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time&#xD;
      phenomena and advanced Parkinson's disease treated with levodopa/carbidopa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actual values and mean change from Baseline in percentage and total hours of awake time per day in the OFF state and ON state, UPDRS I-IV, II and III Scores during ON and OFF states, Global Clinical Impression-Improvement (CGI-I), safety</measure>
  </secondary_outcome>
  <enrollment>325</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istradefylline (KW-6002)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (Steps 1 and&#xD;
             2).&#xD;
&#xD;
          2. Modified Hoehn and Yahr in the OFF state of II-IV.&#xD;
&#xD;
          3. Treated with levodopa/carbidopa for at least one year with a stable regimen for 4&#xD;
             weeks prior to randomization.&#xD;
&#xD;
          4. Taking at least 4 doses of levodopa/carbidopa per day (3 doses if at least 2 doses&#xD;
             contained slow-release formulation) with predictable end of dose wearing off.&#xD;
&#xD;
          5. Successfully competed Parkinson's disease patient diary training with at least 120&#xD;
             minutes of OFF time per day.&#xD;
&#xD;
          6. Stable regimen of other antiparkinson's medications for 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          7. At least 30 years of age and able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with liquid levodopa/carbidopa within 4 weeks of randomization.&#xD;
&#xD;
          2. Treatment with MAO inhibitors except selegiline.&#xD;
&#xD;
          3. Treatment within 3 months with centrally acting dopamine antagonists (6 months for&#xD;
             depot formulations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone,&#xD;
             amoxapine.&#xD;
&#xD;
          4. Neurosurgical operation for Parkinson's disease.&#xD;
&#xD;
          5. Atypical parkinsonism or secondary parkinsonism variants.&#xD;
&#xD;
          6. Diagnosis of cancer or evidence of continued disease within 5 years.&#xD;
&#xD;
          7. Clinically significant illness of any organ system (e.g., ALT or AST &gt; 1.5 times the&#xD;
             upper limit of normal).&#xD;
&#xD;
          8. Mini-Mental Status Examination score of 25 or less.&#xD;
&#xD;
          9. History of drug or alcohol abuse or dependence within 2 years.&#xD;
&#xD;
         10. History of psychotic illness or seizures.&#xD;
&#xD;
         11. Clinically relevant depression disorder.&#xD;
&#xD;
         12. History of neuroleptic malignant syndrome.&#xD;
&#xD;
         13. Pregnancy or lactation. Women of child bearing potential must use a reliable method of&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sussman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Kirin, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Kyowa Pharmaceutical, Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <keyword>Parkinson's disease</keyword>
  <keyword>Levodopa</keyword>
  <keyword>End of dose wearing off</keyword>
  <keyword>OFF time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Istradefylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

